Research Article

The Role of Circulating Tight Junction Proteins in Evaluating Blood Brain Barrier Disruption following Intracranial Hemorrhage

Table 3

Circulating TJs and cytokines in patients with intracranial hemorrhage and the controls.

 Intracranial hemorrhageControls

CLDN5 (pg/mL)1302.35 (669.72–2103.04)157.28 (107.48–213.82)
CLDN5 (pg/mL)89.62 (80.18–117.07)125.79 (103.07–125.79)
OCLN (pg/mL)10.30 (7.22–14.26)0.55 (0.39–1.48)
OCLN (pg/mL)12.56 (8.75–13.54)10.95 (9.63–10.95)
ZO-1 (pg/mL)934.46 (712.03–1161.35)181.08 (138.46–214.08)
ZO-1 (pg/mL)2007.96 (1506.78–2647.24)2173.48 (1678.81–2173.48)
CLDN5/OCLN145.55 (75.62–225.66)268.65 (116.65–452.29)
CLDN5/OCLN7.77 (6.24–12.02)11.48 (10.70–13.26)
CLDN5/ZO-11.34 (0.76–2.08)0.93 (0.57–1.39)
CLDN5/ZO-10.0489 (0.0413–0.0587)0.0579 (0.0403–0.0579)
VEGF (ng/mL)33.16 (25.42–87.43)9.21 (8.38–10.03)
MMP-9 (ng/mL)0.29 (0.20–0.69)0.10 (0.09–0.13)

CLDN5: serum Claudin-5; OCLN: serum Occludin; ZO-1: serum ZO-1; CSF: cerebrospinal fluid; CLDN5: Claudin-5 in CSF; OCLN: OCLN in CSF; ZO-1: ZO-1 in CSF; VEGF: vascular endothelial growth factor; MMP-9: metalloproteinases.
when the intracranial hemorrhage group is compared with control.